SEER vs. AKYA, PRE, RPID, NAUT, PACB, ACET, LIFE, CTXR, KPTI, and RGLS
Should you be buying Seer stock or one of its competitors? The main competitors of Seer include Akoya Biosciences (AKYA), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Nautilus Biotechnology (NAUT), Pacific Biosciences of California (PACB), Adicet Bio (ACET), aTyr Pharma (LIFE), Citius Pharmaceuticals (CTXR), Karyopharm Therapeutics (KPTI), and Regulus Therapeutics (RGLS). These companies are all part of the "medical" sector.
Akoya Biosciences (NASDAQ:AKYA) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Akoya Biosciences has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences has a net margin of -72.68% compared to Akoya Biosciences' net margin of -529.52%. Akoya Biosciences' return on equity of -20.69% beat Seer's return on equity.
79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 7.3% of Akoya Biosciences shares are owned by company insiders. Comparatively, 15.0% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Akoya Biosciences currently has a consensus price target of $7.79, indicating a potential upside of 301.33%. Seer has a consensus price target of $7.00, indicating a potential upside of 253.54%. Given Seer's stronger consensus rating and higher possible upside, analysts plainly believe Akoya Biosciences is more favorable than Seer.
Akoya Biosciences has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
In the previous week, Akoya Biosciences had 3 more articles in the media than Seer. MarketBeat recorded 6 mentions for Akoya Biosciences and 3 mentions for Seer. Akoya Biosciences' average media sentiment score of -0.01 beat Seer's score of -0.05 indicating that Seer is being referred to more favorably in the news media.
Akoya Biosciences received 25 more outperform votes than Seer when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
Summary
Akoya Biosciences beats Seer on 11 of the 17 factors compared between the two stocks.
Get Seer News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
